Indications for KRINTAFEL:
Prevention of P. vivax malaria relapse in patients who are receiving appropriate antimalarial therapy for acute P. vivax infection (eg, chloroquine).
Limitations of Use:
Not for treatment of acute P. vivax malaria.
Swallow whole. Take with food. ≥16yrs: 300mg (2 tabs) as a single dose on the first or second day of antimalarial therapy.
<16yrs: not established.
G6PD deficiency or unknown status. Nursing mothers when infant is G6PD deficient or status unknown.
Must test for G6PD deficiency prior to initiation. Monitor for hemolysis; treat if occurs. NADH-dependent methemoglobin reductase deficiency; monitor. History of psychiatric illness; evaluate benefits vs risks. Discontinue and treat if hypersensitivity reactions occur. Renal or hepatic impairment: monitor. Exclude pregnancy status prior to initiation. Pregnancy: not recommended. Advise females of reproductive potential to use effective contraception during and for 3 months after dose. Nursing mothers: not recommended (during and for 3 months after dose) in G6PD-deficient infant or status unknown.
Avoid concomitant OCT2 and MATE substrates (eg, dofetilide, metformin); if unavoidable, monitor and consider dose reduction of substrate if needed.
Dizziness, nausea, vomiting, headache, decreased hemoglobin; hemolytic anemia, methemoglobinemia, psychiatric effects, hypersensitivity reactions.